PriceTargets.com logo

Aurinia Pharmaceuticals - AUPH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 21.24%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.31 As of 03/24/2023 01:00 AM ET
▲ +1.02 (10.98%)

This chart shows the closing price for AUPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUPH

Analyst Price Target is $12.50
▲ +21.24% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $12.50, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 21.24% upside from the last price of $10.31.

This chart shows the closing price for AUPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Aurinia Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2023Royal Bank of CanadaReiterated RatingOutperform$11.00Low
1/3/2023Royal Bank of CanadaBoost TargetOutperform$10.00 ➝ $11.00Low
11/7/2022HC WainwrightLower TargetBuy$26.00 ➝ $14.00Low
11/4/2022Royal Bank of CanadaLower TargetOutperform$18.00 ➝ $10.00Low
11/4/2022SVB LeerinkLower TargetOutperform$17.00 ➝ $12.00Low
11/4/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
8/9/2022HC WainwrightLower TargetBuy$30.00 ➝ $26.00Low
8/8/2022OppenheimerLower TargetOutperform$15.00 ➝ $13.00Low
8/5/2022Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $18.00Low
5/4/2022HC WainwrightLower Target$33.00 ➝ $30.00High
4/28/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/28/2022Royal Bank of CanadaLower TargetOutperform$27.00 ➝ $22.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/8/2022SVB LeerinkLower TargetOutperform$30.00 ➝ $22.00High
3/1/2022HC WainwrightReiterated RatingBuy$40.00 ➝ $33.00Low
3/1/2022Royal Bank of CanadaLower TargetOutperform$31.00 ➝ $27.00Medium
2/23/2022Royal Bank of CanadaLower TargetOutperform$34.00 ➝ $31.00High
12/15/2021Jefferies Financial GroupReiterated RatingBuyHigh
12/10/2021OppenheimerUpgradeMarket Perform ➝ Outperform$33.00 ➝ $31.00High
11/4/2021OppenheimerBoost TargetMarket Perform$32.00 ➝ $33.00Low
11/4/2021HC WainwrightBoost TargetBuy$35.00 ➝ $40.00Medium
11/4/2021SVB LeerinkBoost TargetOutperform$28.00 ➝ $35.00Medium
10/28/2021OppenheimerDowngradeOutperform ➝ Market Perform$28.00 ➝ $32.00Medium
10/26/2021Royal Bank of CanadaBoost TargetOutperform$23.00 ➝ $34.00High
10/1/2021Bloom BurtonInitiated CoverageHold$23.00Medium
8/19/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021Bloom BurtonUpgradeAccumulate ➝ BuyHigh
5/7/2021Royal Bank of CanadaLower TargetOutperform$26.00 ➝ $23.00Medium
5/7/2021OppenheimerReiterated RatingBuyHigh
4/11/2021SVB LeerinkReiterated RatingBuyMedium
2/25/2021Royal Bank of CanadaLower TargetOutperform$28.00 ➝ $26.00Low
1/27/2021SVB LeerinkBoost TargetOutperform$24.00 ➝ $28.00High
1/26/2021Royal Bank of CanadaBoost TargetAverage ➝ Outperform$20.00 ➝ $28.00High
1/26/2021Cantor FitzgeraldBoost TargetOverweight$27.00 ➝ $34.00High
1/25/2021OppenheimerBoost Target$20.00 ➝ $28.00High
1/25/2021HC WainwrightBoost TargetBuy$30.00 ➝ $35.00High
12/18/2020HC WainwrightBoost TargetBuy$28.00 ➝ $30.00Medium
12/17/2020OppenheimerReiterated RatingBuy$20.00Medium
11/12/2020Cantor FitzgeraldLower Target$30.00 ➝ $26.00Low
11/3/2020Bloom BurtonDowngradeBuy ➝ AccumulateLow
11/3/2020HC WainwrightLower TargetBuy$34.00 ➝ $28.00Medium
8/13/2020Royal Bank of CanadaReiterated RatingBuyLow
8/12/2020HC WainwrightBoost TargetBuy$33.00 ➝ $34.00Low
7/22/2020HC WainwrightBoost TargetBuy$32.00 ➝ $33.00Medium
6/16/2020BTIG ResearchInitiated CoverageBuy$20.00Low
5/17/2020Royal Bank of CanadaReiterated RatingBuy$20.00Low
5/14/2020OppenheimerInitiated CoverageBuy$22.00Low
5/5/2020CowenInitiated CoverageOutperformHigh
4/20/2020HC WainwrightReiterated RatingBuy$32.00High
3/19/2020Bloom BurtonReiterated RatingBuy$23.00Low
3/9/2020Royal Bank of CanadaReiterated RatingBuyMedium
3/6/2020Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $32.00High
1/10/2020Jefferies Financial GroupInitiated CoverageBuy$27.00Medium
12/16/2019HC WainwrightBoost TargetBuy$25.00 ➝ $32.00Low
12/5/2019Cantor FitzgeraldBoost Target$24.00 ➝ $30.00Low
12/5/2019OppenheimerBoost Target$14.00 ➝ $22.00Low
12/5/2019Royal Bank of CanadaBoost TargetOutperform$11.00 ➝ $20.00N/A
11/1/2019HC WainwrightSet TargetBuy$25.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
10/2/2019Bloom BurtonReiterated RatingBuyLow
9/10/2019OppenheimerInitiated CoverageOutperform$14.00 ➝ $14.00High
9/9/2019CitigroupInitiated CoverageOutperform$14.00High
8/8/2019Royal Bank of CanadaReiterated RatingBuy$11.00Medium
6/4/2019HC WainwrightReiterated RatingBuy$25.00Low
5/23/2019HC WainwrightReiterated RatingBuy$15.00 ➝ $25.00Medium
5/15/2019HC WainwrightReiterated RatingBuyHigh
3/20/2019Raymond JamesBoost TargetOutperform$9.00 ➝ $11.00High
3/20/2019Royal Bank of CanadaBoost TargetOutperform ➝ Positive$9.00 ➝ $11.00High
3/19/2019Cantor FitzgeraldReiterated RatingBuy$18.00 ➝ $24.00High
10/1/2018Cantor FitzgeraldSet TargetBuy$18.00Medium
9/26/2018HC WainwrightReiterated RatingBuy$15.00Low
9/25/2018Cantor FitzgeraldSet TargetBuy$18.00Medium
8/13/2018HC WainwrightBoost TargetBuy$15.00High
8/11/2018Cantor FitzgeraldSet TargetBuy$18.00High
7/11/2018Cantor FitzgeraldSet TargetBuy$16.00High
5/16/2018Cantor FitzgeraldSet TargetBuy$16.00Medium
5/10/2018Cantor FitzgeraldReiterated RatingBuy$16.00High
5/2/2018HC WainwrightReiterated RatingBuy$12.00Low
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/28/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: $10.31
Low: $9.22
High: $10.66

50 Day Range

MA: $8.80
Low: $7.61
High: $10.31

52 Week Range

Now: $10.31
Low: $4.07
High: $13.41

Volume

8,338,512 shs

Average Volume

3,062,760 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Aurinia Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Royal Bank of Canada, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for AUPH.

What is the current price target for Aurinia Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 21.2%. HC Wainwright has the highest price target set, predicting AUPH will reach $14.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $11.00 for Aurinia Pharmaceuticals in the next year.
View the latest price targets for AUPH.

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AUPH will outperform the market and that investors should add to their positions of Aurinia Pharmaceuticals.
View the latest ratings for AUPH.

What other companies compete with Aurinia Pharmaceuticals?

Other companies that are similar to Aurinia Pharmaceuticals include DICE Therapeutics, Dynavax Technologies, Day One Biopharmaceuticals, Travere Therapeutics and CinCor Pharma. Learn More about companies similar to Aurinia Pharmaceuticals.

How do I contact Aurinia Pharmaceuticals' investor relations team?

Aurinia Pharmaceuticals' physical mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company's listed phone number is 250-708-4272 and its investor relations email address is [email protected] The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. Learn More about contacing Aurinia Pharmaceuticals investor relations.